![]() | |
Clinical data | |
---|---|
Other names | PH10; PH10A; PH10 NS; Pregn-4-en-20-yn-3-one |
Routes of administration | Intranasal (spray) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C21H28O |
Molar mass | 296.454 g·mol−1 |
3D model (JSmol) | |
| |
|
Itruvone (INN ; developmental code name PH10), also known as pregn-4-en-20-yn-3-one, is a vomeropherine which is under development by VistaGen Therapeutics as a nasal spray for the treatment of major depressive disorder.[1][2][3][4][5][6]
See also
References
- ^ "PH-10 Nasal Spray". AdisInsight. Springer Nature Switzerland AG.
- ^ Monti L, Liebowitz MR (February 2022). "Neural circuits of anxiolytic and antidepressant pherine molecules". CNS Spectr. 27 (1): 66–72. doi:10.1017/S109285292000190X. PMID 33092667. S2CID 225053518.
- ^ "VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depressive Disorder Demonstrated in Phase 2a Study :: VistaGen Therapeutics, Inc. (VTGN)". VistaGen Therapeutics, Inc. Retrieved 2019-12-19.
- ^ "Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more". www.bizjournals.com. San Francisco Business Times. October 29, 2018. Retrieved 20 July 2020.
- ^ Liebowitz MR, Nicolini H, Monti L, Hanover R (2013). PH 10 may be a new rapidly acting intranasally administered antidepressant. Vol. American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Miami, FL.
- ^ Jancin B (2013). "Novel intranasal antidepressant shows results after 1 week". Clinical Psychiatry News. Retrieved 13 January 2016.